5.10
2.00%
+0.10
Syros Pharmaceuticals Inc. stock is currently priced at $5.10, with a 24-hour trading volume of 143.39K.
It has seen a +2.00% increased in the last 24 hours and a -5.56% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.03 pivot point. If it approaches the $5.14 resistance level, significant changes may occur.
Previous Close:
$5.00
Open:
$5.01
24h Volume:
143.39K
Market Cap:
$136.31M
Revenue:
$9.94M
Net Income/Loss:
$-164.57M
P/E Ratio:
-0.9114
EPS:
-5.5956
Net Cash Flow:
$-109.98M
1W Performance:
+2.62%
1M Performance:
-5.56%
6M Performance:
+85.45%
1Y Performance:
+32.47%
Syros Pharmaceuticals Inc. Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc.
Sector
Industry
Phone
617 744 1340
Address
35 CambridgePark Drive, 4th Floor, Cambridge
Syros Pharmaceuticals Inc. Stock (SYRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-22-20 | Initiated | Alliance Global Partners | Buy |
Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
Feb-14-19 | Resumed | Oppenheimer | Outperform |
Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
Mar-13-18 | Reiterated | Wedbush | Outperform |
Oct-31-17 | Resumed | Piper Jaffray | Overweight |
Oct-23-17 | Initiated | ROTH Capital | Neutral |
Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc. Stock (SYRS) Latest News
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick - MSN
MSN
Syros Pharmaceuticals (NASDAQ:SYRS) Shares Cross Below 50 Day Moving Average of $5.25 - MarketBeat
MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Stock Crosses Below 50-Day Moving Average of $5.25 - Defense World
Defense World
Stock Surge: Syros Pharmaceuticals Inc. (SYRS) Closes at 5.05, Marking a 1.00 Increase/Decrease – DWinneX - The Dwinnex
The Dwinnex
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
(SYRS) Trading Advice - Stock Traders Daily
Stock Traders Daily
Syros Pharmaceuticals Inc. Stock (SYRS) Financials Data
Syros Pharmaceuticals Inc. (SYRS) Revenue 2024
SYRS reported a revenue (TTM) of $9.94 million for the quarter ending December 31, 2023, a -33.23% decline year-over-year.
Syros Pharmaceuticals Inc. (SYRS) Net Income 2024
SYRS net income (TTM) was -$164.57 million for the quarter ending December 31, 2023, a -73.87% decrease year-over-year.
Syros Pharmaceuticals Inc. (SYRS) Cash Flow 2024
SYRS recorded a free cash flow (TTM) of -$109.98 million for the quarter ending December 31, 2023, a +11.53% increase year-over-year.
Syros Pharmaceuticals Inc. (SYRS) Earnings per Share 2024
SYRS earnings per share (TTM) was -$5.80 for the quarter ending December 31, 2023, a +54.81% growth year-over-year.
Syros Pharmaceuticals Inc. Stock (SYRS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Roth David | Chief Medical Officer |
Apr 02 '24 |
Sale |
4.98 |
150 |
747 |
10,451 |
AKKARAJU SRINIVAS | Director |
Dec 21 '23 |
Buy |
4.42 |
904,977 |
3,999,998 |
1,786,427 |
Roth David | Chief Medical Officer |
Dec 12 '23 |
Sale |
4.95 |
6,287 |
31,121 |
0 |
Roth David | Chief Medical Officer |
Dec 06 '23 |
Sale |
3.95 |
6,287 |
24,834 |
6,287 |
Roth David | Chief Medical Officer |
Jul 31 '23 |
Sale |
3.95 |
7,348 |
29,025 |
0 |
Olson Eric R | Chief Scientific Officer |
Jul 17 '23 |
Sale |
3.50 |
689 |
2,412 |
6,661 |
About Syros Pharmaceuticals Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):